Intellectual Property

MacuSight has more than 20 issued patents and 70 pending applications worldwide covering its technologies, including:

• Use of mTOR inhibitors, including sirolimus, related compounds and other select therapeutics in the eye
• Comprehensive ocular formulations for mTOR inhibitors
• Minimally invasive, sustained ocular formulations
• Target tissue concentrations, dosing and routes of administration

• Sirolimus
• Therapeutic Action
• Safety
• Intellectual Property